Florida Research Institute

Lakewood Rch, Florida 34238

7 studies enrolling now · 40 studies all time

What they study most

Cirrhosis, Cirrhosis, Liver, Colitis, Ulcerative, Colorectal Cancer, Crohn's Disease, Decompensated Cirrhosis, Diabetes Mellitus, Type 2, Digestive System Diseases, Fatty Liver, Nonalcoholic, Gastroparesis, Inflammatory Bowel Disease, Liver Fibrosis

Studies at this site

• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — Recruiting now
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) — Recruiting now
• LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis — Recruiting now
• LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: — Recruiting now
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) — Running, not enrolling
• A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) — Running, not enrolling
• Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis — Stopped early
• Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment. — Running, not enrolling
• Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) — Completed
• A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis — Running, not enrolling
• A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) — Running, not enrolling
• Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis — Running, not enrolling
• Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode — Running, not enrolling
• Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis — Completed
• A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) — Running, not enrolling
• Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC) — Completed
• Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) — Completed
• A POC and Dose-Ranging Study of HTD1801 in PSC Patients — Completed
• Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed
• Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease — Stopped early
• RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA) — Completed
• Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH) — Stopped early
• Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease — Stopped early
• Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus — Completed
• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease — Completed
• A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients — Completed
• Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD) — Completed
• Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) — Completed
• Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) — Completed
• A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) — Completed
• Diabetic Gastroparesis Study 05 — Stopped early
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis — Completed
• Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis — Stopped early
• Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH — Completed
• Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) — Stopped early
• Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis — Status unconfirmed